Poxel MSN: Why This Platform Is Gaining Attention
Poxel MSN and what users are actually seeking
There is no legitimate connection between Poxel MSN and Marist education, Catholic schools, or any educational authority in Brazil and Latin America. The query "poxel msn" appears to be a navigational search error where users are actually looking for Poxel SA, the French clinical-stage biopharmaceutical company headquartered in Lyon, founded in 2009, while "MSN" is likely a mistaken addition or confusion with Microsoft's MSN portal.
What Poxel Actually Is
Poxel S.A. is a clinical-stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate approved for type 2 diabetes treatment in Japan since December 2021.
Key Facts About Poxel SA
| Attribute | Detail |
|---|---|
| Company Name | Poxel S.A. |
| Founded | 2009 |
| Headquarters | Lyon, France |
| CEO | Thomas Kuhn |
| Employees | 53 (as of 2023) |
| Stock Exchange | Euronext Paris (EPA: POXEL) |
| Market Cap | €20.5M (August 31, 2023) |
| Lead Drug Candidate | Imeglimin (TWYMEEG) |
Why Users Search "Poxel MSN"
The search term "poxel msn" likely stems from typographical confusion or autocorrect errors when users attempt to find information about Poxel's stock ticker, investor relations page, or news coverage. MSN is commonly associated with Microsoft's news portal, leading users to mistakenly append it when searching for business news about Poxel SA.
- Users seeking stock information for EPA: POXEL on Euronext Paris
- Investors looking for financial reports and investor relations materials
- Patients or healthcare professionals searching for Imeglimin treatment information
- Researchers seeking data on MASH clinical trials including the DESTINY-1 Phase 2 trial
Poxel's Clinical Pipeline
Poxel has developed a portfolio of drug candidates targeting mitochondrial dysfunction, with three primary candidates in development. The company's research focuses on metabolic diseases including type 2 diabetes and liver diseases such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN).
- Imeglimin (TWYMEEG) - Approved for type 2 diabetes in Japan (December 2021), targets mitochondrial dysfunction
- PXL065 - Deuterium-stabilized R-pioglitazone, met primary endpoint in Phase 2 DESTINY-1 trial for MASH
- PXL770 - AMPK activator in development for NASH treatment
Marist Education Authority Clarification
As the Marist Education Authority, we establish elite authority in Catholic and Marist education across Brazil and Latin America by articulating a clear, values-driven perspective that blends educational rigor with spiritual and social mission. There is no pharmaceutical company, educational program, or Marist initiative called "Poxel MSN" within our network of schools or partnerships.
School administrators, educators, policymakers, parents, and partners seeking reliable guidance on Marist pedagogy, curriculum innovation, governance, and community engagement should consult official Marist education resources rather than pharmaceutical company information.
Conclusion: Navigating Search Confusion
When encountering ambiguous search queries like "poxel msn," users should verify the correct terminology before proceeding. For pharmaceutical research, consult official company sources; for Marist education, access authorized educational networks. This approach ensures accurate information retrieval aligned with your actual needs, whether in healthcare, education, or investment decisions.
Key concerns and solutions for Poxel Msn Why This Platform Is Gaining Attention
What Should I do if I searched "poxel msn" looking for Marist schools?
If you searched "poxel msn" while looking for Marist educational institutions, you likely experienced a typing error. Marist schools in Brazil and Latin America can be found through official Marist education networks, with prominent institutions including Marist School and Marist High School in Chicago offering Catholic college-preparatory education on 55+ acre campuses with 31 athletic teams.
Is Poxel SA connected to any educational programs?
No, Poxel SA is exclusively a biopharmaceutical company focused on developing treatments for metabolic diseases and has no educational programs, school partnerships, or connections to Marist pedagogy or Catholic education initiatives.
Where can I find legitimate Poxel SA investor information?
Legitimate investor information for Poxel SA is available on their official investor relations page at poxelpharma.com/en_us/investors, where they publish financial reports, clinical trial updates, and stock information for EPA: POXEL on Euronext Paris.
What is the correct spelling for the diabetes drug from Poxel?
The correct spelling is Imeglimin (brand name TWYMEEG), an oral drug approved in Japan for type 2 diabetes treatment that targets mitochondrial dysfunction, developed by Poxel S.A. since the company's incorporation in 2009.
